Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2023-05-12 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
北京市金杜律师事务所关于深圳证券交易所《关于对哈尔滨誉衡药业股份有限公司2022年年报的问询函》相关事项的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm (King & Wood Mallesons) in response to an inquiry letter from the Shenzhen Stock Exchange regarding the 2022 annual report of Harbin Yuheng Pharmaceutical Co., Ltd. The document discusses compliance with approval procedures and disclosure obligations related to investments in an associate company, and it references the 2022 annual report and related audit reports. It is a legal opinion addressing specific questions about the annual report, not the annual report itself. The document is lengthy (15,000 characters) and contains detailed legal analysis and verification, but it is not the full annual report or audit report. It is a standalone audit-related legal opinion responding to regulatory inquiry about the annual report. Therefore, it fits best under the category Audit Report / Information (AR). FY 2022
2023-05-12 Chinese
关于参加黑龙江辖区上市公司2023年投资者网上集体接待日活动的公告
Investor Presentation Classification · 90% confidence The document is a short announcement (622 characters) from Harbin Yuheng Pharmaceutical Co., Ltd. about participating in a 2023 investor online reception day organized by regulatory and industry bodies. It mentions the company will have senior management interact with investors regarding 2022 annual performance, governance, strategy, financing plans, and sustainability. There is no detailed financial data or full report content, only an invitation to an event for investor communication. The document is not a full Annual Report (10-K), Earnings Release, or Management Discussion. It is an announcement about an investor event, which aligns best with Investor Presentation (IP) as it focuses on communicating financials, strategy, and market position to investors. The document is not a report publication announcement or regulatory filing as it does not mention report release or certification. Therefore, the classification is Investor Presentation (IP) with high confidence.
2023-05-10 Chinese
2022年度独立董事述职报告（薛挥）
Management Reports Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Director's Work Report." It contains detailed independent opinions on various company matters such as board meetings, shareholder meetings, related party transactions, internal control evaluations, audit firm reappointment, remuneration plans, and other governance-related activities. The content focuses on the independent director's duties, opinions, and oversight activities during the year 2022. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or certification but a detailed report on management and governance activities by the independent director. This aligns best with the category of Management Reports (MDA), which include management's detailed explanations of business trends, governance, and outlook. Therefore, the document is classified as a Management Reports (MDA).
2023-04-23 Chinese
2022年度营业收入扣除事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (Special Audit Report) regarding the 2022 fiscal year revenue deduction items of Harbin Yuheng Pharmaceutical Co., Ltd. It is issued by a certified public accounting firm and includes detailed audit opinions and a revenue deduction schedule. The document references the 2022 fiscal year and contains audit findings related to revenue deductions, which is a specialized audit report rather than a full annual report or interim report. It is not a general annual report (10-K), nor is it a simple announcement or certification. The document is a standalone audit-related report focusing on a specific audit area (revenue deductions) and the auditor's opinion on it. Therefore, it fits best under the category Audit Report / Information (AR). The document length (5787 characters) and content confirm it is a full report, not just an announcement or certification. FY 2022
2023-04-23 Chinese
关于以抵押子公司资产的方式为银团贷款进行补充担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the provision of additional collateral by mortgaging subsidiary assets to secure a syndicated loan. It details the loan amount, collateral specifics, involved banks, and board authorization. There is no financial statement or detailed financial report included, nor is it a transcript or presentation. The document is a formal announcement about financing and collateral arrangements, which fits the category of Capital/Financing Update (CAP). The document length is 2611 characters, which is consistent with an announcement rather than a full report.
2023-04-23 Chinese
2022年监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度监事会工作报告' which translates to '2022 Supervisory Board Work Report'. It is a detailed report from the supervisory board reviewing their activities, oversight of financials, governance, internal controls, and other supervisory functions for the year 2022. The document includes detailed descriptions of meetings held, opinions on company operations, financial status, internal controls, and plans for 2023. It is not an announcement of a report but the report itself. The content is substantive and covers governance and supervisory oversight rather than full financial statements or audit opinions. This aligns best with an Audit Report / Information (AR) category, which includes supervisory board reports and audit-related oversight documents that are standalone and not full annual reports. The document length is under 5,000 characters but contains detailed supervisory content, not just a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2022
2023-04-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.